Proteomic approach toward personalized sarcoma treatment: Lessons from prognostic biomarker discovery in gastrointestinal stromal tumor

Tadashi Kondo, Yoshiyuki Suehara, Kazutaka Kikuta, Daisuke Kubota, Takashi Tajima, Kenta Mukaihara, Hiroshi Ichikawa, Akira Kawai

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Sarcomas range from curable tumors to those causing death via metastasis and recurrence. Thus, there is an urgent need for biomarker identification in order to assess the degree of malignancy, predict prognosis, and evaluate possible therapies. Various proteomic approaches and different clinical materials have been used to this end, and candidate biomarkers have been reported for the different types of sarcomas. However, the sample size used in these biomarker studies was generally insufficient, and thus far, no biomarker has been proved useful in clinics. Given that sarcomas are rare, biomarker validation in this setting is more challenging than in other malignancies. In gastrointestinal stromal tumor, adjuvant therapy has proven to be effective. However, only 40% patients experience metastasis after curative surgery alone, and the rest of the patients may not need adjuvant therapy. Using a proteomic approach, we identified pfetin (potassium channel tetramerization domain containing 12, KCTD 12) as a novel prognostic biomarker for sarcoma, and immunohistochemically confirmed its clinical usefulness by a multiinstitutional validation study. Here, we describe our experience and discuss the critical points in the discovery of this biomarker.

Original languageEnglish
Pages (from-to)70-78
Number of pages9
JournalProteomics - Clinical Applications
Volume7
Issue number1-2
DOIs
Publication statusPublished - 2013 Jan

Fingerprint

Gastrointestinal Stromal Tumors
Biomarkers
Sarcoma
Proteomics
Tumors
Therapeutics
Neoplasm Metastasis
Neoplasms
Validation Studies
Potassium Channels
Sample Size
Surgery
Recurrence

Keywords

  • Biomarker
  • Sarcoma

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

Proteomic approach toward personalized sarcoma treatment : Lessons from prognostic biomarker discovery in gastrointestinal stromal tumor. / Kondo, Tadashi; Suehara, Yoshiyuki; Kikuta, Kazutaka; Kubota, Daisuke; Tajima, Takashi; Mukaihara, Kenta; Ichikawa, Hiroshi; Kawai, Akira.

In: Proteomics - Clinical Applications, Vol. 7, No. 1-2, 01.2013, p. 70-78.

Research output: Contribution to journalArticle

Kondo, Tadashi ; Suehara, Yoshiyuki ; Kikuta, Kazutaka ; Kubota, Daisuke ; Tajima, Takashi ; Mukaihara, Kenta ; Ichikawa, Hiroshi ; Kawai, Akira. / Proteomic approach toward personalized sarcoma treatment : Lessons from prognostic biomarker discovery in gastrointestinal stromal tumor. In: Proteomics - Clinical Applications. 2013 ; Vol. 7, No. 1-2. pp. 70-78.
@article{c6c09775f2f24a0ea9701decdf9f49b8,
title = "Proteomic approach toward personalized sarcoma treatment: Lessons from prognostic biomarker discovery in gastrointestinal stromal tumor",
abstract = "Sarcomas range from curable tumors to those causing death via metastasis and recurrence. Thus, there is an urgent need for biomarker identification in order to assess the degree of malignancy, predict prognosis, and evaluate possible therapies. Various proteomic approaches and different clinical materials have been used to this end, and candidate biomarkers have been reported for the different types of sarcomas. However, the sample size used in these biomarker studies was generally insufficient, and thus far, no biomarker has been proved useful in clinics. Given that sarcomas are rare, biomarker validation in this setting is more challenging than in other malignancies. In gastrointestinal stromal tumor, adjuvant therapy has proven to be effective. However, only 40{\%} patients experience metastasis after curative surgery alone, and the rest of the patients may not need adjuvant therapy. Using a proteomic approach, we identified pfetin (potassium channel tetramerization domain containing 12, KCTD 12) as a novel prognostic biomarker for sarcoma, and immunohistochemically confirmed its clinical usefulness by a multiinstitutional validation study. Here, we describe our experience and discuss the critical points in the discovery of this biomarker.",
keywords = "Biomarker, Sarcoma",
author = "Tadashi Kondo and Yoshiyuki Suehara and Kazutaka Kikuta and Daisuke Kubota and Takashi Tajima and Kenta Mukaihara and Hiroshi Ichikawa and Akira Kawai",
year = "2013",
month = "1",
doi = "10.1002/prca.201200085",
language = "English",
volume = "7",
pages = "70--78",
journal = "Proteomics - Clinical Applications",
issn = "1862-8346",
publisher = "Wiley-VCH Verlag",
number = "1-2",

}

TY - JOUR

T1 - Proteomic approach toward personalized sarcoma treatment

T2 - Lessons from prognostic biomarker discovery in gastrointestinal stromal tumor

AU - Kondo, Tadashi

AU - Suehara, Yoshiyuki

AU - Kikuta, Kazutaka

AU - Kubota, Daisuke

AU - Tajima, Takashi

AU - Mukaihara, Kenta

AU - Ichikawa, Hiroshi

AU - Kawai, Akira

PY - 2013/1

Y1 - 2013/1

N2 - Sarcomas range from curable tumors to those causing death via metastasis and recurrence. Thus, there is an urgent need for biomarker identification in order to assess the degree of malignancy, predict prognosis, and evaluate possible therapies. Various proteomic approaches and different clinical materials have been used to this end, and candidate biomarkers have been reported for the different types of sarcomas. However, the sample size used in these biomarker studies was generally insufficient, and thus far, no biomarker has been proved useful in clinics. Given that sarcomas are rare, biomarker validation in this setting is more challenging than in other malignancies. In gastrointestinal stromal tumor, adjuvant therapy has proven to be effective. However, only 40% patients experience metastasis after curative surgery alone, and the rest of the patients may not need adjuvant therapy. Using a proteomic approach, we identified pfetin (potassium channel tetramerization domain containing 12, KCTD 12) as a novel prognostic biomarker for sarcoma, and immunohistochemically confirmed its clinical usefulness by a multiinstitutional validation study. Here, we describe our experience and discuss the critical points in the discovery of this biomarker.

AB - Sarcomas range from curable tumors to those causing death via metastasis and recurrence. Thus, there is an urgent need for biomarker identification in order to assess the degree of malignancy, predict prognosis, and evaluate possible therapies. Various proteomic approaches and different clinical materials have been used to this end, and candidate biomarkers have been reported for the different types of sarcomas. However, the sample size used in these biomarker studies was generally insufficient, and thus far, no biomarker has been proved useful in clinics. Given that sarcomas are rare, biomarker validation in this setting is more challenging than in other malignancies. In gastrointestinal stromal tumor, adjuvant therapy has proven to be effective. However, only 40% patients experience metastasis after curative surgery alone, and the rest of the patients may not need adjuvant therapy. Using a proteomic approach, we identified pfetin (potassium channel tetramerization domain containing 12, KCTD 12) as a novel prognostic biomarker for sarcoma, and immunohistochemically confirmed its clinical usefulness by a multiinstitutional validation study. Here, we describe our experience and discuss the critical points in the discovery of this biomarker.

KW - Biomarker

KW - Sarcoma

UR - http://www.scopus.com/inward/record.url?scp=84872711867&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872711867&partnerID=8YFLogxK

U2 - 10.1002/prca.201200085

DO - 10.1002/prca.201200085

M3 - Article

C2 - 23281253

AN - SCOPUS:84872711867

VL - 7

SP - 70

EP - 78

JO - Proteomics - Clinical Applications

JF - Proteomics - Clinical Applications

SN - 1862-8346

IS - 1-2

ER -